Technical Analysis for BDTX - Black Diamond Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
26.99 | -6.61% | -1.91 |
BDTX closed down 6.61 percent on Friday, February 28, 2020, on 52 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Historical BDTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -6.61% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Biotechnology Cancer Therapies For Cancer Tyrosine Kinase Receptors Enzymes Oncogenes Epidermal Growth Factor Receptor Kinase Rare Genetic Diseases Erbb
Biotechnology Cancer Therapies For Cancer Tyrosine Kinase Receptors Enzymes Oncogenes Epidermal Growth Factor Receptor Kinase Rare Genetic Diseases Erbb
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 41.79 |
| 52 Week Low | 26.49 |
| Average Volume | 340,277 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 35.97 |
| 10-Day Moving Average | 33.75 |
| Average True Range | 3.42 |
| ADX | 0.0 |
| +DI | 8.60 |
| -DI | 24.10 |
| Chandelier Exit (Long, 3 ATRs ) | 31.54 |
| Chandelier Exit (Short, 3 ATRs ) | 36.74 |
| Upper Bollinger Band | 42.69 |
| Lower Bollinger Band | 29.24 |
| Percent B (%b) | -0.17 |
| BandWidth | 37.40 |
| MACD Line | -2.75 |
| MACD Signal Line | -1.29 |
| MACD Histogram | -1.4583 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 31.12 | ||||
| Resistance 3 (R3) | 31.41 | 30.32 | 30.43 | ||
| Resistance 2 (R2) | 30.32 | 29.27 | 30.18 | 30.20 | |
| Resistance 1 (R1) | 28.66 | 28.62 | 28.12 | 28.37 | 29.97 |
| Pivot Point | 27.57 | 27.57 | 27.30 | 27.43 | 27.57 |
| Support 1 (S1) | 25.91 | 26.52 | 25.37 | 25.62 | 24.01 |
| Support 2 (S2) | 24.82 | 25.87 | 24.68 | 23.78 | |
| Support 3 (S3) | 23.16 | 24.82 | 23.55 | ||
| Support 4 (S4) | 22.87 |
